Clinical Trial: NCT04462276
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Information Provided By: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Last Update Posted: | 2025-01-30 |
Study Overview
Brief Summary
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients. Patients with a response after induction therapy with carboplatin/etoposide and atezolizumab will be included into this study to subsequently receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This trial aims to i.) increase the efficacy of combined atezolizumab- and chemotherapy by adding radiotherapy and ii.) determine the safety and tolerability of the combination of chemotherapeutic, immunological and radiological treatment in the first-line setting of advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for separate biomarker research project.
Official Title
Conditions
Intervention / Treatment
- Drug: Atezolizumab
- Radiation: thoracic radiotherapy (TRT)
Other Study ID Numbers
- TREASURE
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Information Provided By: | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Last Update Posted: | 2025-01-30 |
Study Overview
Brief Summary
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients. Patients with a response after induction therapy with carboplatin/etoposide and atezolizumab will be included into this study to subsequently receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This trial aims to i.) increase the efficacy of combined atezolizumab- and chemotherapy by adding radiotherapy and ii.) determine the safety and tolerability of the combination of chemotherapeutic, immunological and radiological treatment in the first-line setting of advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for separate biomarker research project.
Official Title
Conditions
Intervention / Treatment
- Drug: Atezolizumab
- Radiation: thoracic radiotherapy (TRT)
Other Study ID Numbers
- TREASURE